Dan Kemp PhD Dabt
About Dan Kemp PhD Dabt
Dan Kemp, PhD, Dabt, serves as the Vice President of Nonclinical & Translational Medicine at Asklepios BioPharmaceutical, Inc. He holds a PhD in Pharmacology and Toxicology from the University of North Carolina at Chapel Hill and has extensive experience in the development of various therapeutic modalities.
Work at Asklepios BioPharmaceutical
Dan Kemp serves as the Vice President of Nonclinical & Translational Medicine at Asklepios BioPharmaceutical, Inc. (AskBio) since 2022. In this role, he oversees the development of small molecules, biologics, botanicals, and cell/gene therapies from the discovery phase through Phase II clinical trials. His leadership contributes to the advancement of innovative therapies in the biopharmaceutical sector. Prior to this position, he held the role of Head of Translational Medicine & Pharm/Tox at AskBio from 2021 to 2022.
Education and Expertise
Dan Kemp obtained his Doctor of Philosophy (PhD) in Pharmacology and Toxicology from the University of North Carolina at Chapel Hill. He also holds a Bachelor's degree in Biochemistry from Michigan State University. His educational background provides a strong foundation for his expertise in managing the development of various therapeutic modalities, including small molecules and gene therapies.
Background
Before joining Asklepios BioPharmaceutical, Dan Kemp worked at IQVIA as the Senior Director of Regulatory Toxicology from 2019 to 2021. His experience in regulatory toxicology complements his current role, enhancing his ability to navigate the complexities of drug development and regulatory requirements. He has a comprehensive understanding of the scientific and business aspects of the biopharmaceutical industry.
Achievements
Dan Kemp has a proven track record in developing scientific strategies and business plans within the biopharmaceutical field. He has successfully managed profit and loss (P&L) responsibilities and has demonstrated his ability to deliver transformative pipelines. His experience includes building and leading multidisciplinary teams, which has been instrumental in advancing clinical initiatives.